Trial Profile

A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 03 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs INCB 160058 (Primary)
Indications Myelofibrosis; Myeloproliferative disorders
Focus Adverse reactions
Sponsors Incyte Corporation

Most Recent Events

29 Oct 2024 Accroding to an Incyte corporation media release, initial data from this study is expected in 2025.
16 Jul 2024 Planned initiation date changed from 14 Jun 2024 to 22 Jul 2024.
16 Jul 2024 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com